CasNx provides ex‑vivo CRISPR‑based genome editing platforms that treat donor organs on perfusion pumps. Their Cas 1x system removes latent viruses, Cas 2x creates universal donor organs by deleting HLA genes and adding tolerance markers, and Cas 3x enhances graft longevity by activating protective genes and suppressing fibrosis, enabling safer and longer‑lasting transplants.
Funding
Funding not disclosed
Founders
Product
Problem
Many donor organs carry latent viruses such as CMV and BKV, and a significant proportion are discarded or fail after transplantation due to HLA incompatibility and chronic rejection. These issues limit organ availability and reduce patient outcomes.
Solution
CasNx applies ex‑vivo CRISPR‑based genome editing to donor organs while they are on perfusion pumps. The Cas 1x platform delivers a one‑shot antiviral treatment that eliminates latent viral contaminants directly on the organ. The Cas 2x platform removes immunogenic HLA genes and inserts universal donor markers, creating organs that can be transplanted without HLA matching and with reduced need for lifelong immunosuppression. The Cas 3x platform introduces a gene‑cocktail that activates cytoprotective pathways and silences fibrosis drivers, pre‑conditioning the graft to resist injury and extending its functional lifespan. All modifications are performed during the short perfusion window, after which the edited organ is returned to the transplant team for implantation.
Target Audience
Primary customers are organ procurement organizations, transplant centers, and biotech partners that prepare donor kidneys, livers, and hearts for clinical transplantation.
Features
- Ex‑vivo CRISPR delivery integrated into standard organ perfusion pumps for seamless treatment during the preservation phase
- Cas 1x antiviral editing that targets and clears CMV, BKV, and other latent viruses in a single treatment
- Cas 2x universal donor editing that deletes HLA antigens and inserts tolerance markers to eliminate immune matching requirements
- Cas 3x longevity editing that up‑regulates cytoprotective genes and down‑regulates fibrosis drivers to double graft lifespan
- Proprietary precision editing pipelines that ensure targeted genetic modifications without off‑target effects
- Fully ex‑vivo workflow requiring no additional surgical steps or post‑transplant interventions